Crohn’s Disease Serum

Crohn’s Disease Serum for Immune-Mediated Inflammatory Bowel Disease Research

Our Crohn’s Disease Serum is sourced from IRB-consented donors clinically diagnosed with Crohn’s disease. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for inflammation and immunology studies. Crohn’s disease is an immune-mediated inflammatory bowel disease driven by a dysregulated mucosal response to the gut microbiota in genetically susceptible individuals, not by a classical autoantibody response.

Why Serum for Crohn’s Disease Research

• Serum is the conventional matrix for the antibody assays used in IBD serology, including anti-Saccharomyces cerevisiae antibodies (ASCA), anti-OmpC and pANCA. ASCA are antibodies to a microbial antigen rather than autoantibodies, and the ASCA-positive/pANCA-negative pattern is used to help differentiate Crohn’s disease from ulcerative colitis.
• Serum removes fibrinogen and most clotting factors, giving a lower-viscosity, lower-interference matrix for many commercial ELISA and multiplex immunoassay kits validated on serum.
• Crohn’s inflammation is driven by the IL-12/IL-23, Th1/Th17 and TNF axis. Serum supports quantification of the circulating mediators of that axis, including TNF, IL-6, IL-17A and IL-22, alongside acute-phase CRP.
• Biologic trough concentrations and anti-drug antibodies against anti-TNF, anti-IL-23 and anti-integrin therapies are routinely measured in serum, making it the practical matrix for therapeutic drug monitoring assay development.
• Serum from stricturing disease supports research on extracellular matrix turnover and fibrosis markers, which reflect the transmural remodelling that distinguishes Crohn’s disease from mucosa-limited colitis.
• Because clotting activates platelets and complement, serum and plasma are not interchangeable for those analytes; ordering matched serum and plasma from the same donors lets teams anchor cross-matrix comparability.

Donor Stratification Available

• Disease activity, including clinical remission versus active flare, with Harvey-Bradshaw Index or CDAI where documented
• Montreal classification: age at diagnosis, disease location (ileal, colonic, ileocolonic, upper GI) and behaviour (non-stricturing, stricturing, penetrating)
• Serology and laboratory results where available, including ASCA status, CRP and faecal calprotectin
• Treatment status: biologic-naive, anti-TNF, anti-IL-12/23 or anti-IL-23, anti-integrin, JAK inhibitor, corticosteroid or immunomodulator
• Surgical and complication history, including prior resection, ostomy and perianal fistulising disease
• Matched healthy controls available, as well as ulcerative colitis donors for IBD subtype comparison

Product Features

• Collected from clinically confirmed Crohn’s disease donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Standard and custom aliquot volumes; volumes reported per lot
• Matched plasma and whole blood from the same donors available on request

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Medication history and Crohn’s disease-specific metadata available on request

Applications

• ASCA, anti-OmpC and pANCA serology assay development and IBD subtype discrimination
• Serum cytokine and inflammatory protein profiling across the TNF and IL-23/Th17 axes
• Biomarker discovery and validation for disease activity and mucosal healing
• Therapeutic drug monitoring and anti-drug antibody assay development
• Fibrosis and extracellular matrix turnover marker research in stricturing disease
• Serum proteomics and metabolomics
• Therapeutic candidate screening and target validation
• Disease-state control matrix for immunoassay qualification and kit validation

Other Crohn’s Disease Specimen Types

• Crohn’s Disease Plasma
• Crohn’s Disease Whole Blood
• Crohn’s Disease PBMC
• Crohn’s Disease Leukopak
• Crohn’s Disease Bulk Plasma
• Crohn’s Disease CD19+ B Cells

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Crohn’s disease serum is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human serum page.